|Awarded On||August 20, 2014|
|Title||Preclinical Drug Discovery and Development of Novel, First-In-Class, Small Molecule Compounds That Directly Target Glioblastoma and Other Brain Cancers|
|Program||Product Development Research|
|Award Mechanism||New Company Product Development Award|
|Institution/Organization||Curtana Pharmaceuticals, Inc.|
|Principal Investigator/Program Director||Gregory Stein|
|Cancer Sites||Brain and Other Nervous System, Childhood and Adolescent|
Curtana Pharmaceuticals is developing the first truly targeted small molecule drug for the treatment of glioblastoma (GBM), diffuse intrinsic pontine glioma (DIPG), and other brain cancers. GBM is the most common and deadliest of the malignant primary brain tumors in adults. DIPG, which occurs in the brainstem, is one of the most deadly pediatric brain tumors.
Curtana is applying for a New Company Product Development Award to bring a novel, first-in-class therapy from the laboratory to clinical trials in patients within 3 years. Support for Curtana’s drug development program fits with CPRIT’s mission to expedite innovation in the area of new product development and to attract companies to Te...